MPM: Frontier Medicines Receives $80M in Series C Financing

Frontier Medicines Corporation, a Boston, MA- and San Francisco, CA-based precision medicine company developing therapies against otherwise undruggable disease-causing targets, received $80M in Series C funding. The round, which brought the total amount to$235.5M, was led by Deerfield Management Company and Droia Ventures, with participation from Galapagos NV (Euronext & NASDAQ: GLPG) as a strategic investor, and contributions [...]The post Frontier Medicines Receives $80M in Series C Financing appeared first on FinSMEs.